Previous close | 0.5100 |
Open | 0.5100 |
Bid | 0.0500 |
Ask | 1.0500 |
Strike | 2.50 |
Expiry date | 2024-10-18 |
Day's range | 0.5100 - 0.5100 |
Contract range | N/A |
Volume | |
Open interest | 128 |
We feel now is a pretty good time to analyse Xeris Biopharma Holdings, Inc.'s ( NASDAQ:XERS ) business as it appears...
CHICAGO, June 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing’s syndrome at ENDO 2024 in Boston, June 1-4, 2024.
CHICAGO, May 30, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection